Tailong Investment

Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases.

Mainstream Bio is a biotechnology company grounded in research, specializing in the development of innovative peptide therapeutics 2.0.

Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

BiyoPharma focuses on the research and development of innovative drugs for neurological diseases, including episodic and chronic migraines, through international technology platforms and improved treatment options.

Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.

LeadBio Tech is a biotechnology company focused on developing bioartificial blood vessel medical devices. It specializes in tissue engineering and regeneration solutions to replace and repair human tissues and organs. The company's flagship product is degradable bioartificial blood vessels based on skeleton immune wrapping technology, designed for use in arteriovenous grafts (AVG) surgeries. These advanced artificial vessels aim to improve patient outcomes by providing superior alternatives to traditional vascular access methods.

Cytocares Technology specializes in the research and development of innovative macromolecule drugs aimed at tumor immunotherapy. The company focuses on creating novel medications that enhance tumor immunity, targeting both hematological tumors and solid tumors. By leveraging advanced drug design techniques, Cytocares strives to provide effective treatments and therapeutic options for patients facing various types of tumors, contributing to the advancement of cancer care.

Lab Direct is a company founded in 2014 and headquartered in Shanghai, China, that specializes in developing an online supply chain and procurement service platform. This platform is designed to facilitate direct connections between laboratories, research institutions, and suppliers, allowing users to access essential equipment and supplies efficiently. By streamlining the procurement process, Lab Direct enhances the ability of laboratories and research entities to secure the necessary products for their operations, ultimately supporting their research and operational needs.

Haixin zhihui is an artificial intelligence company. They offer intelligent diagnosis, and treatment systems for tumor diseases have been developed. They provide patients with precise treatment recommendations and assist patients in treatment planning and full disease management.